Trials / Withdrawn
WithdrawnNCT02742805
Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Selina Gierer, D.O. · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The proposed research is intended to determine if supplementation of relatively high dose vitamin D in chronic urticaria patients receiving omalizumab will result in continued symptomatic control of hives after the discontinuation of omalizumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Vitamin D (4,000 IU/day) | High Dose of 4,000 IU/day. |
| DIETARY_SUPPLEMENT | Vitamin D (400 IU/day) | Low Dose of 400 IU/day. |
| DRUG | Omalizumab | Standard of care dose. |
Timeline
- Start date
- 2016-02-01
- Primary completion
- 2018-12-01
- Completion
- 2019-12-01
- First posted
- 2016-04-19
- Last updated
- 2018-05-01
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02742805. Inclusion in this directory is not an endorsement.